|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||22.88 - 22.88|
|52-week range||22.88 - 22.88|
|Beta (5Y monthly)||0.72|
|PE ratio (TTM)||23.37|
|Earnings date||02 Aug 2021 - 06 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also...
Corcept's (CORT) Cushing's syndrome drug, Korlym, is making good progress. Other pipeline candidates are advancing as well. However, sole dependence on Korlym for growth remains an overhang.
Endo's (ENDP) earnings and sales beat estimates in the first quarter, driven by revived demand.